Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.96
-0.34 (-5.40%)
At close: May 15, 2026, 4:00 PM EDT
6.08
+0.12 (2.01%)
After-hours: May 15, 2026, 7:58 PM EDT

Taysha Gene Therapies Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
277.03320.22139.49144.3987.88149.1
Cash & Short-Term Investments
277.03320.22139.49144.3987.88149.1
Cash Growth
136.69%129.57%-3.40%64.30%-41.06%-40.66%
Other Current Assets
5.234.432.655.488.5410.5
Total Current Assets
282.25324.65142.13149.8796.42159.6
Net Property, Plant & Equipment
15.6116.1815.8720.4125.9150.61
Other Long-Term Assets
2.52.52.372.463.953.74
Total Assets
300.35343.32160.36172.73126.28213.96
Accounts Payable
4.566.283.596.3710.9521.76
Accrued Expenses
15.5320.2812.8612.2818.2929.98
Unearned Revenue
--9.7718.1133.56-
Total Current Liabilities
20.126.5526.2336.7662.7951.75
Long-Term Debt
48.9650.1143.9440.5137.9737.19
Long-Term Leases
17.7718.1717.3618.9520.4425.9
Other Long-Term Liabilities
1.581.551.311.584.133.74
Total Long-Term Liabilities
68.3169.8362.6161.0462.5466.83
Total Liabilities
88.4196.3888.8497.79125.33118.57
Common Stock
00000-
Additional Paid-in Capital
964.67958.43677.86587.94402.39331.03
Accumulated Other Comprehensive Income
0.99-0.19-4.03---
Retained Earnings
-753.71-711.3-602.31-513.01-401.44-235.65
Shareholders' Equity
211.94246.9471.5374.940.9595.38
Total Liabilities & Equity
300.35343.32160.36172.73126.28213.96
Total Debt
66.7368.2861.359.4658.4163.09
Net Cash (Debt)
210.3251.9478.1884.9329.4786.01
Net Cash Growth
-16.53%222.25%-7.94%188.16%-65.73%-65.77%
Net Cash Per Share
0.610.790.310.730.672.28
Book Value
211.94246.9471.5374.940.9595.38
Book Value Per Share
0.620.770.290.650.022.53
Tangible Book Value
211.94246.9471.5374.940.9595.38
Tangible Book Value Per Share
0.620.770.290.650.022.53
Updated May 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q